Sign in
Taking people in United StatesPhase 2

Pulsed low-dose-rate whole brain radiation for cancer spread to the brain

Tests pulsed whole brain radiation with memantine for brain metastases.

Key facts

Who runs it
Medical College of Wisconsin
Where
Milwaukee, United StatesSee the 2 sites
Trial code
Registry title
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
Status
Recruiting
Phase
Phase 2
People taking part
53 people, planned
Started
17 Nov 2021
Expected to end
May 2029
Type of study
Interventional
Treatments tested
  • Memantine -Twice Daily or Extended Release
  • WBRT utilizing the PRDR technique
Record updated
29 July 2026

Who can take part

The trial is looking for adults whose cancer has spread to the brain from a solid tumour. They will get whole-brain radiation given in a low-dose-rate pulsed way, plus memantine.

Age
18 years or older at diagnosis of brain metastases.
Sex
All sexes can join.
Disease stage
Brain metastases from a solid tumour, proven by biopsy, that can be measured on scans. ECOG performance score below 2 (able to care for yourself). Expected to live more than six months given the cancer outside the brain. Largest tumour no more than 5 cm (2 in) across if not removed.
Earlier treatment
Earlier cancer drug treatment is allowed. Earlier radiosurgery (SRS) or surgery for brain metastases is allowed, finished at least 7 days (SRS) or 14 days (surgery) before joining. People who had whole-brain radiation before cannot join.
Biomarker or test result
Creatinine clearance of ≥ 30 mL/min.
Main reasons for not taking part
  • Metastases from a blood cancer or a cancer that started in the brain or spinal cord
  • Cancer spread to the brain's lining (leptomeningeal metastases), or cancer treated with the aim of removing all of it
  • Cannot have MRI with contrast, or cannot take memantine
  • Stage IV-V chronic kidney disease or end-stage kidney disease, or dementia not linked to the brain metastases
  • Pregnancy, unwillingness to use birth control, or English not the native language
Show the full registry criteria (25)Hide the full registry criteria

Who can take part

  • Age ≥18 years at diagnosis of brain metastases
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of <2
  • Participants must have a biopsy-proven solid malignancy (histologic proof or unequivocal cytologic proof solid tumor malignancy from either the primary or any metastatic site) with intracranial lesions radiographically consistent with or pathologically proven to be brain metastases
  • Patients who have undergone prior systemic therapy are eligible
  • Life expectancy from extracranial disease greater than six months
  • Patients with measurable brain metastasis
  • Patients may have had prior therapy for brain metastasis, including stereotactic radiosurgery (SRS)and surgical resection. Patients must have completed prior therapy by at least 7 days prior to study enrollment for SRS and at least 14 days for surgical resection
  • If an open biopsy is performed, the patient must be at least one-week post-biopsy. This requirement is not necessary for stereotactic biopsies
  • Creatinine clearance is ≥ 30 mL/min
  • Start of PRDR WBRT within two weeks following registration
  • Ability to complete the Neurocognitive Function (NCF) test battery (including people whose primary language is English)
  • Patients with previous or other malignancies whose disease is controlled and not impacting ECOG performance or life expectancy
  • Willing and able to give consent and to comply with treatment and follow-up schedule

Who cannot take part

  • Patients whose malignancy is being treated with curative intent
  • Contraindication to memantine including concurrent use of N-methyl-D-aspartate (NMDA) antagonists
  • Prior cranial whole brain radiation therapy
  • Women of childbearing potential who are known to be pregnant or are unwilling to use an acceptable method of contraception from the time of informed consent until completion of the course of radiotherapy
  • Metastases from hematological malignancy, or central nervous system malignancy
  • Stage IV-V chronic kidney disease or end-stage renal disease
  • Past medical history of dementia which is thought to be unrelated to the brain metastases
  • Patients must not have a serious medical or psychiatric illness that would, in the opinion of the treating physician, prevent informed consent or completion of protocol treatment, and/or follow-up visits
  • Leptomeningeal metastases
  • Contraindication to MRI imaging with contrast
  • Participants with a maximum tumor diameter exceeding 5 cm (if not resected)
  • Non-native English speakers will be excluded since patients often lose their faculty with the language they acquired second before their native language is affected in the context of cognitive decline. This could adversely affect performance on verbal cognitive tasks

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Brain metastases

This trial is currently available in United States.

  • Clement J. Zablocki Veterans Affairs Medical CenterMilwaukee, United StatesContact: Amber Bishop, MS, MATaking people
  • Froedtert Hospital & the Medical College of WisconsinMilwaukee, United StatesContact: Lindsay Puckett, MDTaking people

About the trial

What the trial wants to find out

Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.

The group in the trial

  • WBRT-PRDR plus memantine.Treatment being tested

    Study patients will receive WBRT-PRDR within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique. Memantine should ideally start two days (or one day) prior to WBRT PRDR and must start no later than the fourth WBRT PRDR treatment and will continue for a maximum of 24 weeks (≈six months). Memantine will be administered as per standard institutional guidelines.

    Treatment: Memantine -Twice Daily or Extended Release and WBRT utilizing the PRDR technique

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole-Brain Radiation Therapy for Brain Metastases
Plain-language title
Pulsed low-dose-rate whole brain radiation for cancer spread to the brainGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT05045950, who can take part
Record updated
29 July 2026